TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Inclusion Criteria

• •1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;
• •2. presence of PVTT with III-IV grade by Cheng's criteria;
• •3. having PVTT induced portal hypertension;
• •4. with or without PVTT induced acute variceal bleeding;
• •5. metastases with limited five sites and no more two organs involved;
• •6. Number of Intrahepatic tumors were no more than five;
• •7. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy;
• •8. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;
• •9. no history of other malignancies;
• •10. agreed to participated in this clinical trial;
• •11. Hemameba ≥3.0 x109/L, neutrophil ≥1.5x109/L, hemoglobin≥10.0 g/L, platelet≥100x 109/L, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml/min.